A facile synthesis of alpha,alpha'-(EE)-bis(benzylidene)-cycloalkanones and their antitubercular evaluations

An economical and facile synthesis of alpha,alpha'-(EE)-bis(benzylidene)-cycloalkanones was achieved by the reaction of cycloalkanones with different aromatic aldehydes using ethanolic KOH in good yields. Few of the selected compounds were reduced with NaBH(4) to the respective alpha,alpha'-(EE)-bis(benzylidene)-cycloalkanols. All these compounds and our earlier synthesized cyclohexyl phenyl methanols were evaluated for their antitubercular, antifungal and antibacterial activities. Several compounds displayed moderate antitubercular activity with MIC=12.5-1.56 microg/mL. However, none of the compounds displayed any significant antifungal activity.     

Gene therapy to prevent occlusion of venous bypass grafts

Revascularization with vein grafts is standard surgical therapy for occlusive arterial diseases. Autologous saphenous vein grafts are important conduits for repairing blocked coronary arteries and are used in the majority of vein graft procedures. Up to 50% of saphenous vein grafts will be occluded during the first decade after surgery. Vein graft occlusion occurs as a result of neointimal hyperplasia, which takes place in response to hemodynamic changes and vessel wall injury, and is characterized by the migration and proliferation of vascular smooth muscle cells. Intimal hyperplasia is further complicated by the concomitant development of atherosclerosis and thrombosis. In the absence of effective pharmacological interventions for the treatment and prevention of occlusive vein graft disease, gene therapy has emerged as a potential therapeutic alternative. Gene therapy could improve vein graft patency by reducing early thrombosis, neointimal hyperplasia and atherosclerosis. In this review we will summarize the emerging applications of gene therapy as a therapeutic tool in occlusive vein graft disease.     

A study on utilization of anti–asthmatic drugs at a medical college hospital in India

ObjectiveTo study the usage of anti-asthmatic dugs and enumerate the patients' non-compliance.MethodsThe study was conducted from 5th Feb, 2006 to 5th Mar, 2006. The samples were from the general medicine ward. All patients with respiratory tract infection who received anti–asthmatic drugs were included in the study. Data were collected from clinical notes and structured patient's data, and patient interview utilizing a piloted questionnaire data collection form. The questionnaire included patient demographics, anti–asthmatics prescribed, dose, frequency and previous treatment if any and its duration, concomitant medications etc.Results26.31% of patients were 61–70 years old. Among 57 patients, 91.23% of patients received multi–therapy, 8.77% of patients received mono–therapy, 59.65% of patients took over the counter (OTC) drugs and 57.89% of patients were non compliant. Anti–asthmatic drugs were prescribed to asthmatic patients as oral, inhalation and others (injections), and more than one route were used for administration of drugs.ConclusionThe anti-asthmatics are used to treat breathing difficulties such as allergy. Poor compliance to treatment is common among the patients, which makes it difficult to manage asthma and increases both morbidity and mortality. It is suggested that interventions have to be done by providing counseling and improving the current prescribing trend for better and rational utilization.     

Part‐time consultants in radiation oncology

The aim of this study was to evaluate the attitudes and experiences of staff towards radiation oncologists who work part‐time. A questionnaire was sent to all radiation oncologists, radiation oncology registrars and radiation therapists, and a nursing and clerical representative working in all radiation oncology departments throughout Australia and New Zealand. Of 1242 questionnaires, 446 (35.9%) were returned. Of these, 323 out of 435 respondents (74.2%) supported the concept of a radiation oncologist working part‐time. The main barriers to part‐time work were inadequate provision of cover, the inability to be contacted when not rostered on, and perceived reduced quality of patient care. The majority of respondents supported part‐time employment in radiation oncology. However, the conclusions made from this survey are limited by the poor response rate. For a successful part‐time career in radiation oncology, the following points need to be ensured: (i) an equitable pro‐rata workload that encompasses both clinical and non‐clinical duties; (ii) a clear and well‐publicised timetable that is strictly adhered to with special emphasis on completing work prior to non‐rostered days; (iii) clear mechanisms in place to deal with patient or other queries on non‐rostered days; (iv) a mechanism for being contacted for urgent problems; and (v) good communication between the part‐time radiation oncologist, other staff and patients.     

Challenges related to human papillomavirus (HPV) vaccine uptake in Minnesota: clinician and stakeholder perspectives

Background

Human papillomavirus (HPV) vaccination rates among adolescents are increasing in Minnesota (MN) but remain below the Healthy People 2020 goal of 80% completion of the series. The goal of this study was to identify messaging and interventions impacting HPV vaccine uptake in MN through interviews with clinicians and key stakeholders.

Methods

We conducted semi-structured key participant interviews with providers and stakeholders involved in HPV vaccination efforts in MN between 2018 and 2019. Provider interview questions focused on messaging around the HPV vaccine and clinic-based strategies to impact HPV vaccine uptake. Stakeholder interview questions focused on barriers and facilitators at the organizational or state level, as well as initiatives and collaborations to increase HPV vaccination. Responses to interviews were recorded and transcribed. Thematic content analysis was used to identify themes from interviews.

Results

14 clinicians and 13 stakeholders were interviewed. Identified themes were grouped into 2 major categories that dealt with messaging around the HPV vaccine, direct patient–clinician interactions and external messaging, and a third thematic category involving healthcare system-related factors and interventions. The messaging strategy identified as most useful was promoting the HPV vaccine for cancer prevention. The need for stakeholders to prioritize HPV vaccination uptake was identified as a key factor to increasing HPV vaccination rates. Multiple providers and stakeholders identified misinformation spread through social media as a barrier to HPV vaccine uptake.

Conclusion

Emphasizing the HPV vaccine’s cancer prevention benefits and prioritizing it among healthcare stakeholders were the most consistently cited strategies for promoting HPV vaccine uptake. Methods to combat the negative influence of misinformation about HPV vaccines in social media are an urgent priority.